Austausch mit Impfstoffherstellern und der EMA über die mögliche Herkunft des COVID-19-Virus

This procedure is a written question addressed to the German government regarding discussions with vaccine manufacturers and the European Medicines Agency (EMA). It seeks to clarify what is known about the potential origins of the SARS-CoV-2 virus based on these exchanges. This inquiry affects public health policy and government transparency, focusing on the communication between national authorities, pharmaceutical companies, and EU regulatory bodies.